Bottom line
How much do LFSC and FBDIX overlap?
18% of their top holdings overlap by weight. 6 securities appear in both funds' top 25, making up 24.3% of LFSC's assets and 11.8% of FBDIX's. They are substantially different portfolios, so owning both adds real diversification.
FBDIX holds far more positions (126 vs 40), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings LFSC and FBDIX have in common
| Holding | % of LFSC | % of FBDIX | Overlap |
|---|---|---|---|
| Spyre Therapeutics Inc SYRE | 6.41% | 1.87% | 1.87% |
| Guardant Health Inc GH | 5.52% | 2.76% | 2.76% |
| Mirum Pharmaceuticals Inc MIRM | 4.92% | 1.98% | 1.98% |
| Cytokinetics Inc CYTK | 3.16% | 1.24% | 1.24% |
| Dianthus Therapeutics Inc DNTH | 3.09% | 2.32% | 2.32% |
| Bridgebio Pharma Inc BBIO | 1.17% | 1.67% | 1.17% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in LFSC
- Travere Therapeutics Inc — 7.67%
- Cogent Biosciences Inc — 7.53%
- LivaNova PLC — 7.11%
- Corcept Therapeutics Inc — 4.79%
- United Therapeutics Corp — 4.16%
- VeraDermics Inc — 3.42%
- Savara Inc — 3.22%
- Nektar Therapeutics — 3.14%
- Trevi Therapeutics Inc — 3.12%
- Axsome Therapeutics Inc — 2.84%
- Billiontoone Inc — 2.73%
- TransMedics Group Inc — 2.68%
- Viridian Therapeutics Inc — 2.24%
- ICU Medical Inc — 2.09%
- Corvus Pharmaceuticals Inc — 1.95%
Only in FBDIX
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Ascendis Pharma A/S — 2.56%
- Insmed, Inc. — 1.99%
- Praxis Precision Medicines, Inc. — 1.91%
- Oruka Therapeutics, Inc. — 1.86%
- Neurocrine Biosciences, Inc. — 1.82%
- PTC Therapeutics, Inc. — 1.65%
- AstraZeneca plc — 1.51%
Asset mix
| Asset type | LFSC | FBDIX |
|---|---|---|
| Stocks | 100.0% | 97.0% |
| Cash & short-term funds | — | 4.6% |
| Preferred stock | — | 1.0% |
| Other | — | 0.6% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Country mix
| Country | LFSC | FBDIX |
|---|---|---|
| US | 92.0% | 82.0% |
| GB | 7.1% | 1.5% |
| IE | — | 6.7% |
| NL | — | 4.5% |
| DK | — | 2.6% |
| FR | — | 1.7% |
| CA | — | 1.3% |
| CH | — | 1.2% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Check another pair
FAQ
How much do LFSC and FBDIX overlap?
What stocks do LFSC and FBDIX have in common?
Should I own both LFSC and FBDIX?
Which holds more stocks, LFSC or FBDIX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.